

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 March 2024 (14.03.2024)



(10) International Publication Number
WO 2024/051762 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61K 47/65 (2017.01)
A61P 35/00 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:

PCT/CN2023/117376

(22) International Filing Date:

07 September 2023 (07.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/117496

07 September 2022 (07.09.2022) CN

PCT/CN2023/083228

23 March 2023 (23.03.2023) CN

(71) Applicant: **XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.** [CN/CN]; Room 301, Building C29, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215127 (CN).

(72) Inventors: **LI, Zhuolin**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **GUAN, Xuewa**; Room 301, Building

C29, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215127 (CN). **SHANG, Chengzhang**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **SHEN, Yuele**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: The anti-TROP2/EGFR antibodies, and antibody drug conjugates derived therefrom, specifically bind to at least two different antigens EGFR and TROP2.

[Continued on next page]



WO 2024/051762 A1

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*